StockData
CTT Pharmaceutical Holdings, Inc. logo

CTT Pharmaceutical Holdings, Inc. (CTTH) stock

CTTHOTCPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2015, quý kết thúc ngày Sep 30, 2015Last filing: 10-Q on Nov 18, 2026
$0.06−0.00 (-0.17%)

Close on Oct 16, 2026Market cap $1.26MP/E –Yield –

Key statistics

Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2015

Valuation

Market cap
$1.26M
P/E ratio
–
Price to sales
–
Price to book
1.70
Dividend yield
–
Free cash flow yield
–

Fundamentals

Net income
-$1.67M
EPS, diluted
-$0.03
Book value per share
$0.03
Diluted shares
21M

Trading

Previous close
$0.06
Open
$0.05
Day's range
$0.05 – $0.06
Volume
2,999
Average volume (20 days)
24,006

Market cap history

Month-end market cap since 2011, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Oct 16, 2026. The S&P 500 is measured by the SPY fund.

PeriodCTTHS&P 500DifferenceCTTH per yearS&P 500 per year
1 month+23.0%+1.5%+21.5 pts
3 months-3.4%+1.9%−5.4 pts
Year to date-2.0%+12.8%−14.8 pts
1 year-29.3%+16.8%−46.1 pts
3 years+1800.0%+81.5%+1718.5 pts+166.8%+22.0%
5 years+24.8%+83.0%−58.2 pts+4.5%+12.8%
10 years+17.8%+319.4%−301.6 pts+1.7%+15.4%

Fifteen years at a glance

Fiscal years 2000 to 2014 and trailing twelve months, USD

Operating income

–

Net income

-$1.67M

EPS, diluted

-$0.03
Reported periodTrailing twelve months

Press releases

Releases CTT Pharmaceutical filed with the SEC as exhibits to Form 8-K or 6-K

About CTT Pharmaceutical

Pharmaceutical Preparations

Mindesta Inc. is a development-stage pharmaceutical technology company focused on drug delivery systems. Operating through its wholly owned subsidiary, CTT Pharmaceuticals, Inc., the company specializes in fast-dissolving oral thin wafers designed to carry pharmaceutical agents. Its primary focus is creating cannabis-infused wafers containing natural or synthetic cannabinoids for pain management and treating the side effects of cancer therapy, offering an alternative to smoking or swallowing pills. The company targets patients requiring fast-acting relief, such as individuals suffering from acute or persistent pain, as well as pediatric and geriatric patients who experience difficulty swallowing conventional medications.

Company profile, executives and history

CTT Pharmaceutical stock: common questions

What is CTT Pharmaceutical's stock price?

CTTH closed at $0.06 on Oct 16, 2026, down 0.17% on the day.

What is CTT Pharmaceutical's market cap?

CTT Pharmaceutical was worth $1.26M at the close on Oct 16, 2026: the share price times the diluted shares outstanding.

What is CTTH's P/E ratio?

CTT Pharmaceutical lost money over the twelve months to Sep 30, 2015 (diluted EPS -$0.03), so it has no meaningful P/E ratio.

Does CTT Pharmaceutical pay a dividend?

No. CTT Pharmaceutical has not paid a cash dividend over the last twelve months.

How has CTTH stock performed over the past year?

Including dividends, CTTH returned -29.3% over the past year, against +16.8% for the S&P 500.

Who are CTT Pharmaceutical's competitors?

Companies most similar to CTT Pharmaceutical by business, industry and size include CNBX, SMNR, MTRI, GSAC, DWTX.

See a number that looks wrong?